VivoSim Labs, INC. — Form 8-K
Filed August 6, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
VivoSim received a $5.0M milestone payment from Eli Lilly (FXR program sale), $1.0M from escrow release, and completed a $4.0M financing (net $3.6M) via warrant issuance at $0.85/share on July 17, 2026. These post-fiscal-year-end events brought cash to $10.1M as of August 3, restored stockholders' equity above Nasdaq's $2.5M minimum, and diluted shares from 3.2M to 13.4M outstanding (9.9M new shares issued July 15–31).
Why this rating
For a $7.5M market-cap company, $10M+ cash infusion is transformational; eliminates delisting risk. Major dilution offsets gains somewhat.
See more from August 6, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.